Neurogene (NGNE) Share-based Compensation (2013 - 2026)
Neurogene's (NGNE) quarterly Share-based Compensation came in at $3.6 million in Q1 2026, down 10.35% YoY from $4.0 million in Q1 2025, and up 189.65% on a QoQ basis from -$4.0 million in Q2 2025.
Neurogene (NGNE) Share-based Compensation (2013 - 2026) Analysis & Trends
Neurogene (NGNE) has 14 years of Share-based Compensation data on file, last reported at $3.6 million in Q1 2026.
- Quarterly Share-based Compensation fell 10.35% year-over-year to $3.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$419000.0 (down 110.35% YoY) and the FY2024 annual result came in at $60000.0, down 95.77% from the prior year.
- Share-based Compensation rose to $3.6 million in Q1 2026, from -$4.0 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $5.8 million in Q3 2024 to a low of -$5.8 million in Q4 2024.
- A 5-year average of $454214.3 and a median of $709000.0 in 2023 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2024 — Share-based Compensation sank 1726.2% — and 2025, when it soared 6646.67%.
- Tracing NGNE's Share-based Compensation over 5 years: stood at -$5.5 million in 2022, then surged by 106.41% to $355000.0 in 2023, then slumped by 1726.2% to -$5.8 million in 2024, then grew by 29.88% to -$4.0 million in 2025, then jumped by 189.65% to $3.6 million in 2026.
- The last three Share-based Compensation figures came in at $3.6 million (Q1 2026), -$4.0 million (Q2 2025), and $4.0 million (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Neurogene | 815.03 Mn | 815.03 Mn | - | 7.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.86 Mn |
| Jun 30, 2026 | 7.86 Mn |
| Mar 31, 2026 | 3.63 Mn |
| Mar 31, 2026 | 3.63 Mn |
| Jun 30, 2025 | -4.05 Mn |
| Jun 30, 2025 | -4.05 Mn |
| Mar 31, 2025 | 4.05 Mn |
| Mar 31, 2025 | 4.05 Mn |
| Dec 31, 2024 | -5.77 Mn |
| Dec 31, 2024 | -5.77 Mn |
| Sep 30, 2024 | 5.77 Mn |
| Sep 30, 2024 | 5.77 Mn |
| Mar 31, 2024 | 60,000.00 |
| Mar 31, 2024 | 60,000.00 |
| Dec 31, 2023 | 355,000.00 |
| Dec 31, 2023 | 355,000.00 |
| Sep 30, 2023 | 1.06 Mn |
| Sep 30, 2023 | 1.06 Mn |
| Jun 30, 2023 | -293,000.00 |
| Jun 30, 2023 | -293,000.00 |